Compare Quest Diagnostics Inc (DGX) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Waste Management, Inc. — how do they compare? Quest Diagnostics Inc trades at $230.98 (market cap $25.48B), while Waste Management, Inc. trades at $208.12 (market cap $83.98B). The key difference: Waste Management, Inc. is far larger — about 3.3× Quest Diagnostics Inc's market cap, and Waste Management, Inc. pays the higher dividend (1.8%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Waste Management, Inc. for 130 Days on average.
| DGX | WM | |
|---|---|---|
Market Cap | $25.48B | $83.98B |
Volume | 941,866 | 2,182,180 |
Sector | Health | Industrials |
52-Week High | $247.45 | $246.51 |
52-Week Low | $173.49 | $196.77 |
Typical Hold Time | 56 Days | 130 Days |
Enterprise Value | $31.23B | $106.78B |
Dividend Yield | 1.49% | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
WM trades at $208.94, up 0.51% today, with a bearish technical signal but strong fundamentals including 11.12% net income margin and 29.83% ROE. Recent earnings show beats in Q1 and Q2 2026, while Q4 2025 missed estimates. Revenue grew to $25.20B in 2025, and cash flow from operations remains robust at $6.04B. Analyst sentiment is positive with 54% buy ratings and no sell recommendations.
The outlook is supported by steady revenue growth and high profitability, but risks include elevated debt levels and competitive pressures. The stock's valuation at a P/E of 29.72 may limit near-term upside, though institutional backing and dividend payments provide stability. Investors should weigh solid cash generation against debt concerns and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
